Our portfolio
Jeito Capital is building a strong and diversified portfolio in Biopharma and innovative medical companies.
Neogene Therapeutics
Oncology - Cell Therapy
Sparing Vision
Ophtalmology - Gene Therapy
Pulmocide
Inhaled Respiratory Medicine
Alentis Therapeutics
Cancers and Organ fibrosis
Quell Therapeutics
T-reg cell therapy in auto-immune and inflammatory diseases
Advesya
IMMUNO-ONCOLOGY THERAPIES
NMD Pharma
Severe neuromuscular diseases
EyeBio
Eye disease therapies
Precirix
Oncology therapies
CDR-Life
Immuno-oncology therapies
HI-Bio
Auto-Immune Diseases - Antibody
CatalYm
Immuno-Oncology Therapies
Noema Pharma
DEBILITATING CENTRAL NERVOUS SYSTEM DISORDERS
Corteria Pharmaceuticals
CARDIOVASCULAR DISEASESOncology – Cell therapy
Round of $110 million – September 2020 and Acquisition by AstraZeneca for $320 million – January 2023
Negoene Therapeutics is a preclinical biotechnology company at the forefront of developing next-generation, fully personalized T-cell therapies targeting a wide range of cancers.
On 29 November 2022, AstraZeneca announced its acquisition of Neogene, which was finalised on the 16th of January 2023, for a total consideration of up to $320 million. Through this transaction, AstraZeneca strengthens its cell therapy portfolio that aims to empower and equip the immune system’s T cells, to more effectively fight cancer.
Ophtalmology – Gene Therapy
Rounds of €44,5 million – September 2020 and €75 million – September 2022
SparingVision is specialized in the research and development of ophthalmic treatments, particularly in the field of hereditary retinal degeneration.
Inhaled respiratory medicine
Rounds of $92 million – May 2021 and $52 million – December 2022
Pulmocide is a UK-based biotechnology company developing a leading range of first-in-class inhaled anti-infectives for the targeted treatment of life-threatening lung infections.
Cancers and organ fibrosis
Rounds of €55 million in June 2021, €96 million in April 2023 and €164.5 million in November 2024
Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumors. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alentis is the leading company pioneering anti-CLDN1 ADCs and antibodies to modify and reverse the course of select diseases.
Alentis was founded based on ground-breaking research in the laboratory of Prof. Thomas Baumert, MD at the University of Strasbourg and the French National Institute of Health and Medical Research (Inserm). Alentis is headquartered at the pharma-biotech hub in Basel, Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US.
T-reg cell therapy in auto-immune and inflammatory diseases
Round of $156 million – November 2021
Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.
Immuno-oncology therapies
Round of €23 million – February 2022
Advesya is a pioneering biopharma company for difficult-to-treat cancers.
The creation of Advesya was based on decades of research carried out by experienced scientists from the French Blood Institute (EFS) who spun off the activity in 2021.
Advesya aims to rapidly bring new innovations to the cancer therapy sector, starting with aiding refractory Acute Myeloid Leukemia patients, followed by other hematological malignancies.
Severe neuromuscular diseases
Round of €35 million – February 2022 and €75 million – November 2023
NMD Pharma A/S, is a private biotechnology company leading in the development of novel first-in-class therapies for severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity.
Ophthalmology diseases
Round of $65 million – February 2022 and $65 million – November 2023, and Acquisition by Merck & Co. for up to $3 billion – July 2024
EyeBio is a newly launched global company developing the next generation of eye disease therapies
Founded by two pioneers in ophthalmology drug development to build and advance diversified pipeline of ocular therapies.
Jeito selects EyeBio as its 8th investment and continues to build a strong & diversified portfolio of companies with groundbreaking therapies in areas of high unmet need.
On the 29th of May 2024, Merck & Co (NYSE: MRK) announced its acquisition of EyeBio, which was exited in July 2024, for a total consideration of up to $3 billion.
Oncology therapies
Round of €80 million – March 2022
Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology as its ninth investment.
The financing will allow Precirix to advance its pipeline of precision radiopharmaceuticals.
Immuno-oncology therapies
Round of $76 million – April 2022
CDR-Life is a Swiss biotechnology company at the forefront of a new class of highly tumor-specific immuno-oncology therapeutics.
CDR-Life leverages the unique expertise and track record of its founders, who together have developed new approved drugs and entered into major biotechnology agreements.
Jeito chooses CDR-Life as its 10th investment and continues to build a strong and diversified portfolio of companies with breakthrough therapies in areas of unmet needs.
Auto-Immune Diseases – Antibody
Round of $120 million – November 2022 and $95 million – January 2024, and Acquisition by Biogen Inc. for up to $1.8 billion – July 2024
Human Immunology Biosciences (HI-Bio) is a San Francisco-based Phase II clinical-stage Biopharma company, with European development activities.
HI-Bio develops targeted therapies for patients suffering from severe immune-mediated diseases (IMD). It has several late-stage clinical programmes and a strong translational platform, enabling it to address many diseases with unmet medical needs.
On the 22nd of May 2024, Biogen Inc. (Nasdaq: BIIB) announced its acquisition of HI-Bio, which was exited in July 2024, for a total consideration of up to $1.8 billion.
Immuno-Oncology Therapies
Rounds of €50 million – November 2022 and $150 million – July 2024
CatalYm is a Phase II clinical-stage Biopharma company developing novel immunotherapies to fight cancer. It is based in Munich.
Its lead drug candidate, Visugromab, is a monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15), an inhibitor of immune cell infiltration into the tumor tissue.
DEBILITATING CENTRAL NERVOUS SYSTEM DISORDERS
Round of €104 million – March 2023
Noema Pharma is a clinical-stage biotechnology company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks.
The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche.
CARDIOVASCULAR DISEASES
Round of €65 million – September 2023
Corteria Pharmaceuticals is a late preclinical stage biopharma company, developing first-in-class therapies with promising novel approaches for unaddressed heart failure subpopulations, addressing high unmet medical needs. It is based in France.
The company’s pipeline includes three therapies – including two programmes in-licensed from Sanofi – aimed at treating worsening heart failure, right heart failure and acute heart failure with hyponatremia. The Biopharma has the potential for wider exploitation in chronic cardiometabolic diseases.
At a glance
key data
investments in portfolio
millions euros under management
In short
Discover Jeito news
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.